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Anemia is the decrease in total circulating erythrocytes below the normal cutoff for the corresponding age, race, and sex [1,2]. Anemia has a high prevalence in Asian 
and African countries, whereas thalassemia is the most common 
hemolytic anemia worldwide [3-5]. Mutations of β globin genes 
occur predominantly in children of Mediterranean, Southern, and 
South East Asian ancestry [2]. Prevalence is high in Punjab and 
Sindhis in North India [4,6].
Frequent blood transfusion to mainatin desired hemoglobin 
often leads to depoistion of iron in vital organs such as heart, liver, 
lung spleen and endocrine glands. As a result, complications such 
as growth retardation, endocrine disturbances, and osteoporosis 
occur [7-10]. Cardiac complications are the most common cause of 
death in thalassemia patients. Cardiomyopathy occurs due to chronic 
anemia and tissue hypoxia [11]. The American Heart Association 
consensus statement on the cardiovascular function and treatment in 
β thalassemia major (TM) patients states that the most common cause 
of mortality in transfused patients of TM is heart failure due to iron 
overload [12]. The pathology in thalassemia is not only the hemolysis 
and iron overload but also the adaptation of the heart to the long-
standing anemia. Symptoms of chronic anemia, breathlessness, and 
exercise intolerance mask the clinical diagnosis of failure. Cardiac 
adaptations to chronic anemia such as tachycardia at rest, low blood 
pressure, increased end-diastolic volume, increased ejection fraction, 
and high cardiac output may delay the diagnosis [13,14].
Increased incidence of pulmonary hypertension (PH) and 
arrhythmia is seen in these patients compared to the general 
population. PH is defined as a mean pulmonary artery pressure of 
25 mmHg or above in an individual at rest at the sea level [15]. This 
chain of anemia, hypoxia, vasoconstriction, endothelial injury, 
hypercoagulability, free radical injury, proliferation of smooth 
muscles, and obliteration of pulmonary vasculature recurs many 
times in thalassemia patients which ultimately causes PH [16,17]. 
Free radical injury due to iron in the lungs is also postulated as a 
possibility for the development of PH by immunoinflammatory 
pathway.
Diagnosis of PH in thalassemia patients requires regular and 
periodic screening as the majority of them are asymptomatic. 
Before the advent of iron chelating therapy, chronic severe anemia 
and iron overload were the primary causes for cardiomyopathy 
and mortality in thalassemia [14]. With the introduction of blood 
transfusions and chelation therapy, the morbidity and deaths have 
been pushed a decade later. Clinically alone, it is difficult to pick 
up symptoms of heart failure as symptoms of anemia overlap. 
Hence, these patients need continuous monitoring of symptoms 
and signs aided with investigations for the early detection of 
complications and its management for better outcome.
To detect this pre-symptomatic stage of cardiac complications, 
many techniques are available such as electrocardiogram (ECG), 
echocardiography (2D ECHO), T2-cardiac magnetic resonance 
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imaging (MRI), and Multigated Acquisition Scanning. ECG and 
ECHO are cost-effective, non-invasive, and easily available; 
however, the gold standard to assess the cardiac iron overload 
is done by MRI which is expensive. Disadvantage includes high 
cost, time consumption, non-availability in resource-poor settings, 
claustrophobia, contraindicated in patients with cardiac pacemaker, 
metallic fragments and requires highly skilled personnel for the 
procedure [17]. In India, studies regarding the screening of cardiac 
complication in the first decade in thalassemia cases by ECHO are 
not available so far. Studies from the Middle East have shown that 
ECHO can be used to detect cardiac dysfunction before clinical 
symptoms and sign appear [17-19]. The objective of this study 
was to evaluate the role of non-invasive ECHO as a screening tool 
for the detection of cardiac complications in thalassemia patients 
who are on regular blood transfusion.
METHODS
This study was conducted in a pediatric hospital in Chennai from 
June 2015 to November 2015. A total of 54 β-thalassemia patients 
between 2 and 12 years of age, who were on regular blood transfusion, 
were included in the study. Children with congenital heart disease 
and those with the terminal illness were excluded from the stduy. The 
Institute Ethical Committee clearance was taken, and after obtaining 
consent from the parents, demographic and anthropometry for body 
mass index (BMI), clinical history involving the family history, and 
transfusion details were taken. Investigations, complete blood count, 
chest X-ray, serum ferritin using chemiluminescence technology, 
ECG, and ECHO were done. Doppler ECHO was done as per the 
guidelines of the American Society of ECHO.
Left ventricular (LV) end-diastolic dimension (LVEDD), LV end-
systolic dimension (LVESD), systolic and diastolic interventricular 
septum thickness (IST), and LV posterior wall thickness in systole 
and diastole were calculated using M-mode ECHO. Ejection fraction 
and fractional shortening were also calculated using the same. LV 
mass was calculated using the formula 0.8×1.04×(LVEDD+posterior 
wall thickness + IST) 3-(LVEDD) 3) +0.6, and LV mass index was 
indexed to body surface area. Tricuspid regurgitant (TR) velocity 
was measured by pulsed Doppler. PH was measured using TR jet 
velocity and modified Bernoulli equation (ΔP=4V2). These results 
were tabulated using charts (ECHO in pediatric and congenital heart 
disease, Wiley–Blackwell, Oxford [UK] 2010 for LV dimension, 
and wall thickness) [15]. LV mass and LV mass index by M-mode 
ECHO was calculated by the above formula and tabulated as per the 
percentile charts [15].
Appropriate statistical analysis for means, standard 
deviations, Fisher’s exact test, and coefficient of correction 
values was calculated with 95% confidence intervals, p value at 
5% significance (p<0.05) using SPSS 21.
RESULTS
In our study, 54 children were selected, 34 (63%) were <6 years, 
and 20 (37%) were between 6 and 12 years of age. 57% of 
them were from rural areas with slight male preponderance 
(63%). 24 (44 %) children were born to consanguineous parents. 
3rd month was the earliest age of the diagnosis with mean age of 
diagnosis of 9 months. 47 (87%) of them were of TM and 7 (13%) 
of intermedia. In spite of being on oral chelators, 41 (76%) had 
serum ferritin >1000 ng/ml and only 13 (24%) had <1000 ng/ml. 
Patient with least value of 215 ng/ml had thalassemia intermedia 
(TI), on transfusions once in 3 months. 4 of 7 TI patients had 
ferritin <1000 ng/ml and 3 of them had higher values. Patients 
with low values of ferritin had an average of a total of 30 
transfusions. Of the 47 TM patients, 9 (19%) had serum ferritin 
values <1000 ng/ml, whereas 38 (80.90%) had >1000 ng/ml 
(Table 1).
The ECG results showed that, of the 38 TM patients with high 
ferritin values, 8.5% had right ventricular hypertrophy (RVH) 
on ECG. Serum ferritin had no association with LV hypertrophy 
(LVH) in ECG. 36% (17) of TM had LVH in ECG. QTc interval 
was normal in all patients, and no arrhythmia was noted. Of 47 
TM patients, 32 (67%) had abnormal ECHO findings. Of 38 
TM patients with elevated serum ferritin level, 27 (71.1%) had 
increased LV mass/m2 and 11 (28.9%) cases had normal LV mass 
despite increased serum ferritin level. 3 TM patients with serum 
ferritin <1000 ng/dl had increased LV mass (p=0.034) as shown 
in Table 1.
There was a poor positive correlation between LV mass and 
TR velocity (p=0.06) and poor negative correlation between EF 
and TRV (p=0.477). It indicates that right and LV dysfunction 
can occur independently. In our study, 3 (42%) TI patients and 
10 (21%) TM patients had PH, which showed that the incidence 
of PH was more common in TI than in TM. 8 (62%) of 13 children 
with PH were diagnosed as thalassemia in their infancy (p=0.019). 
Mean hemoglobin in patients with PH was 7. 33±1.13 g, and the 
mean age was 5.38 years. A total of 10 (21.2%) TM children with 
PH had serum ferritin >1000 ng/dl, but PH and serum ferritin had 
no association (p=0.148). 25 TM patients had TR, but there was 
no association with serum ferritin levels (p=0.623) as shown in 
Table 1.
The sensitivity of ECHO in comparison with ECG, in the 
detection of any cardiac complication in thalassemia patient 
on chronic blood transfusion, was 89.47% and specificity was 
45.71%. The negative predictive value of echo was 88.89% as 
shown in Table 2.
DISCUSSION
Patients in the majority of the previous studies conducted 
to assess the cardiovascular complications included patients 
>10 years of age. In our study, 63% were <6 years and 37% 
between 6 and 12 years. In studies by Sayed et al. [18] and Noori 
et al. [19], all the patients were more than 10 years of age and 
Azarkeivan et al. [20] had patients >7 years of age. It was seen 
in these studies that cardiac complications occur early in spite of 
regular blood transfusions and in well-chelated patients.
In our study, 29 (54%) patients had tachycardia, and mean 
hemoglobin in these patients was 7.33±1.13 g/dl; mean EF was 
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70% and fractional shortening was 39.54. Mean LVMI in these 
patients was 79.63 g/m2. Similar results were seen in studies 
done by Sayed et al. [18] and Noori et al. [19]. All patients in 
this study had normal blood pressure for their corresponding age 
and sex. A study by Malik et al. [11] observed that even patients 
with PH had normal systemic blood pressure. In spite of being 
on oral chelators, 76% of the study population had serum ferritin 
>1000 ng/ml as compared to Samira et al. [18] study who had all 
patient with ferritin >1000 ng/ml.
In our study, no association was found with serum ferritin 
and ECG findings of RVH and LVH. In our study, 35 (64%) had 
cardiomegaly on chest X-ray, but 27 (77%) of these patients had 
high serum ferritin values which imply that cardiomegaly in these 
patients can be due to chronic anemia and volume overload rather 
than iron overload alone. Arrhythmia was not seen in this study in 
contrast to Sayed et al. [18] where corrected QT and QT dispersion 
intervals were increased significantly in patients with serum 
ferritin >5000 ng/ml. Ejection fraction was found to be mildly 
elevated than the normal values for age with mean of 69.96% 
in the present study, which was comparable to results of other 
studies by Sayed et al. [18] (66.28%), Mohammad [21] (65%), 
and Azarkeivan et al. [20] (60%). There was a poor negative 
correlation between EF and TR velocity. It indicates that right 
and LV dysfunction can occur independently.
LV mass and LV mass index were increased in 34 (63%) 
patients, and similar findings were observed in studies done by 
Noori et al. [19], Abbas et al. [22], Mosa et al. [21], and Sayed 
et al. [18]. Increase in LV mass and LV mass index in thalassemia 
is multifactorial. It is due to chronic anemia, tissue hypoxia, and 
iron overload, and there was a poor positive correlation between 
LV mass and TR velocity.
Table 1: Demographic and clinical factors and relation with serum ferritin levels
Parameters n (%) p
Age <6 years - 63% (n=34)
6–12 years - 37% (n=20)
Sex Male - 63% (34) and female - 37% (20)
Residence Rural - 57% (31) and urban - 43% (23)
Type TM - 47 and TI - 7
Frequency of transfusion TM - 87% (47) - once per month
TI - 9% (5) - once in 2 months
Malnourished 33%
Heart rate Normal - 46% (n=25)
Tachycardia - 54% (n=29)
Mean hemoglobin 7.33±1.13 g%
Serum ferritin >1000 ng/ml - 76% (n=41) <1000 ng/ml - 24% (n=13)
TI serum ferritin >1000 ng/ml - 42.8% (n=3)
<1000 ng/ml - 57.14% (n=4)
TM serum ferritin >1000 ng/ml - 80.9% (n=38) <1000 ng/ml -19% (n=9)
Serum ferritin and Consanguinity Consanguineous - 24
Non-consanguineous - 30
p=0.413, df=1
Serum ferritin and residence Rural - 31 and urban – 23 p=0.504, df=1




ECHO Mean ejection fraction - 69.96% SD 5.637±0.767
Serum Ferritin with LV mass Increased 63% (34)
Normal 37% (20) 
Pearson correlation 0.064
LV mass on Echo (T major) Increased - 71.1% (n=27)
Normal - 28.9% (n=11) 
p=0.034, df=1
Ejection Fraction 69.96±0.767
Pulmonary artery pressure Increased - 24% (n=13)
Normal - 76% (n=41)
p=0.019, df=1
PH TM - 21.2% (n=10)
TI - 42% (n=3)
PH and serum ferritin >1000 21.2 (n=10) p=0.148, df=1
RVH: Right ventricular hypertrophy, LVH: Right ventricular hypertrophy, TM: Thalassemia major, TI: Thalassemia intermedia, PH: Pulmonary hypertension
Table 2: Wilson score method
Parameter Estimate (%) Lower–Upper 95% 
CIs
Sensitivity 89.47 (68.61, 97.06¹)
Specificity 45.71 (30.47, 61.81¹)
Positive predictive value 47.22 (31.99, 62.99¹)
Negative predictive value 88.89 (67.2, 96.9¹)
Diagnostic accuracy 61.11 (47.79, 72.96¹)
CI: Confidence interval. 1p≤0.05
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PH was seen in 24% in our study, wherein 10 (21%) TM 
and 3 (42%) TI patients had PH. All 10 had serum ferritin 
>1000 ng/ml which shows that PH was more in TI than in TM. 
Sylvia et al. [23] also observed that high prevalence of PH is 
seen in well-transfused TM patients and most importantly in TI 
patients. A total of 8 (62%) of 13 children with PH were diagnosed 
to have thalassemia in their infancy; the incidence of PH showed 
significant association with the age of diagnosis (p=0.019). This 
implies that incidence of PH in TI is high as the age advances; 
however, it had no association with consanguinity, geographical 
distribution, or sex of the patient. In a study by Meloni et al. [24], 
it was seen that, well tnanfused TM paitents had low risk of PH 
than TI. Sylvia et al. [17] also had a high prevalence of PH in TI. 
These patients also had low hemoglobin and high serum ferritin 
than those who did not have PH.
The sensitivity and specificity of ECHO on thalassemia 
patients in our study, when compared to ECG, were found to be 
89.47% and 45.7%, respectively. Negative predictive value was 
89%. Serum ferritin had a poor positive correlation with LV mass 
and PH; hence, it cannot be used as single marker for cardiac iron 
load in transfusion-dependent thalassemia patients. The limitation 
of this study was the ECHO findings which were not compared 
with T2* MRI which is the gold standard in the diagnosis of 
cardiac iron deposition, and the efficacy of this procedure in 
confirming cardiac iron load is less [24]. Further, PH should also 
be confirmed by cardiac catheterization.
CONCLUSION
Our study adds that 2D echo can be used to detect the cardiac 
complication in thalassemia in pre-symptomatic stage. 
Complications can be detected early in asymptomatic children 
by easily available, affordable, and non-invasive technique like 
ECHO.
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